Consistent results were also observed in the MARIPOSA-2 study in patients with EGFR exon 19 deletion, and in L858R mutation advanced NSCLC patients who progressed on or after osimertinib [17]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.